Literature DB >> 30659870

Melanoma prognosis in the United States: Identifying barriers for improved care.

Zachary H Hopkins1, Christopher Moreno2, Ryan Carlisle3, Aaron M Secrest4.   

Abstract

BACKGROUND: Despite improvements in melanoma mortality, disparities in melanoma survival persist. We evaluated possible sociodemographic and health care-based predictors of differences in melanoma survival in the United States by using the melanoma mortality-to-incidence ratio (MIR).
METHODS: State-based MIRs were calculated by using US cancer statistics data from 1999 to 2014. Pearson correlations and linear regressions were used to determine associations between MIR and dermatologist density, primary care provider density, number of physicians by state, number of National Cancer Institute-designated cancer centers, health care spending per capita, average household income, racial/ethnic makeup of the population, percentage of uninsured individuals, and percentage with a bachelor's degree.
RESULTS: The mean overall MIR was 0.15 ± 0.04; only Alaska was an outlier (0.24). No state MIRs increased significantly over time; MIR decreased for most states. Multivariable analysis revealed that states with more active physicians (P = .02) and a higher percentage non-Hispanic whites (P = .004) had higher MIRs (poorer survival). Significant Pearson correlations were seen between MIR and melanoma incidence (r = -0.72, P < .001), melanoma mortality (r = 0.38, P < .001), dermatologist density (r = 0.32, P < .001), and National Cancer Institute-designated cancer center count (r = -0.12, P = .001).
CONCLUSIONS: Melanoma survival is improved in higher-incidence areas and areas with higher dermatologist density. These findings highlight areas of poorer melanoma survival and the need for local studies evaluating disparities in melanoma survival.
Copyright © 2019 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  barriers to care; dermatology; disparities; epidemiology; health care access; melanoma; mortality-to-incidence ratio; prognosis

Mesh:

Year:  2019        PMID: 30659870     DOI: 10.1016/j.jaad.2019.01.003

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  5 in total

1.  Low accuracy of self-reported family history of melanoma in high-risk patients.

Authors:  Nicholas D Flint; Michael D Bishop; Tristan C Smart; Jennifer L Strunck; Kenneth M Boucher; Douglas Grossman; Aaron M Secrest
Journal:  Fam Cancer       Date:  2021-01       Impact factor: 2.375

2.  Incidence and Survival Rates of Cutaneous Melanoma in South Korea Using Nationwide Health Insurance Claims Data.

Authors:  TaeHo Kim; Siyeong Yoon; Dong-Eun Shin; Sang Cheol Lee; Jisu Oh; So-Young Lee; Do Kyung Kim; Segi Kim; Bosung Jung; Minsup Kim; Soonchul Lee
Journal:  Cancer Res Treat       Date:  2021-09-30       Impact factor: 5.036

3.  Pandemic Pressure: Teledermatology and Health Care Disparities.

Authors:  Andrea M Rustad; Peter A Lio
Journal:  J Patient Exp       Date:  2021-02-23

4.  Melanoma Extension for Community Healthcare Outcomes: A Feasibility Study of Melanoma Screening Implementation in Primary Care Settings.

Authors:  Mirna Becevic; Emily Smith; Mojgan Golzy; Ramakrishna Bysani; Adam Rosenfeld; Ellen R Mutrux; Kimberly Hoffman; Emmanuelle Wallach; Jane A McElroy; Karen Edison
Journal:  Cureus       Date:  2021-05-29

5.  Aloin promotes cell apoptosis by targeting HMGB1-TLR4-ERK axis in human melanoma cells.

Authors:  Pan Li; Kai Ren; Yin Yin Liang; Ji Kai Liu; Zhuo Wen Liang; Yong Feng Zhang
Journal:  EXCLI J       Date:  2020-05-14       Impact factor: 4.068

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.